K. Marr, R. Carter, F. Crippa, W. A. Corey, and L. , Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients, Clinical Infectious Diseases, vol.34, issue.7, pp.909-917, 2002.
DOI : 10.1086/339202

J. Barreto, C. Beach, R. Wolf, J. Merten, P. Tosh et al., The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole, American Journal of Hematology, vol.53, issue.4, pp.283-288, 2013.
DOI : 10.1002/ajh.23388

A. Lopez and O. Zaragoza, Update on the epidemiology and diagnosis of invasive fungal infection, Int J Antimicrob Agents, vol.32, pp.143-147, 2008.

H. Ji, W. Zhang, Y. Zhou, M. Zhang, J. Zhu et al., and Its Interaction with Azole Antifungals, Journal of Medicinal Chemistry, vol.43, issue.13, pp.2493-2505, 2000.
DOI : 10.1021/jm990589g

M. Goodwin and R. Drew, Antifungal serum concentration monitoring: an update, Journal of Antimicrobial Chemotherapy, vol.61, issue.1
DOI : 10.1093/jac/dkm389

S. Zhou, J. Liu, and B. Chowbay, Polymorphism of human cytochrome P450 enzymes and its clinical impact, Drug Metabolism Reviews, vol.288, issue.1, pp.89-295, 2009.
DOI : 10.1124/mol.104.008086

V. Hafner, N. Albermann, W. Haefeli, and F. Ebinger, Inhibition of Voriconazole Metabolism by Chloramphenicol in an Adolescent with Central Nervous System Aspergillosis, Antimicrobial Agents and Chemotherapy, vol.52, issue.11, pp.4172-4174, 2008.
DOI : 10.1128/AAC.00805-08

L. Purkins, N. Wood, D. Kleinermans, K. Greenhalgh, and D. Nichols, Effect of food on the pharmacokinetics of multiple-dose oral voriconazole, British Journal of Clinical Pharmacology, vol.691, pp.17-23, 2003.
DOI : 10.1046/j.1365-2125.2003.01994.x

M. Hoenigl, W. Duettmann, R. Raggam, K. Seeber, K. Troppan et al., Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies, Antimicrobial Agents and Chemotherapy, vol.57, issue.7, pp.3262-3267, 2013.
DOI : 10.1128/AAC.00251-13

A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille et al., Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-211, 2008.
DOI : 10.1086/524669

A. Pascual, C. Csajka, T. Buclin, S. Bolay, J. Bille et al., Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections, Clinical Infectious Diseases, vol.55, issue.3, pp.381-390, 2012.
DOI : 10.1093/cid/cis437

J. Smith, N. Safdar, V. Knasinski, W. Simmons, S. Bhavnani et al., Voriconazole Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.50, issue.4, pp.1570-1572, 2006.
DOI : 10.1128/AAC.50.4.1570-1572.2006

H. Chu, R. Jain, H. Xie, P. Pottinger, D. Fredricks et al., Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial, BMC Infect Dis. Clin Infect Dis Off Publ Infect Dis Soc Am, vol.1355, pp.1080-1087, 2012.

M. Dolton, J. Ray, S. Chen, K. Ng, L. Pont et al., Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.56, issue.9, pp.4793-4799, 2012.
DOI : 10.1128/AAC.00626-12

G. Zhanel, D. Saunders, D. Hoban, and J. Karlowsky, Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans, Antimicrobial Agents and Chemotherapy, vol.45, issue.7, pp.2018-2022, 2001.
DOI : 10.1128/AAC.45.7.2018-2022.2001

U. Theuretzbacher, F. Ihle, and H. Derendorf, Pharmacokinetic/Pharmacodynamic Profile of Voriconazole, Clinical Pharmacokinetics, vol.26, issue.7, pp.649-663, 2006.
DOI : 10.2165/00003088-200645070-00002

P. Gandia, C. Arellano, T. Lafont, F. Huguet, L. Malard et al., Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?, Cancer Chemotherapy and Pharmacology, vol.62, issue.Suppl 4, pp.531-536, 2013.
DOI : 10.1007/s00280-012-2035-3

M. Burt, D. Anderson, J. Kloss, and F. Apple, Evidence-based implementation of free phenytoin therapeutic drug monitoring, Clin Chem, vol.46, pp.1132-1135, 2000.

F. Cafini, D. Sevillano, L. Alou, F. Gómez-aguado, M. Corcuera et al., Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology, Rev Esp Quimioter Publ Of Soc Esp Quimioter, vol.25, pp.47-55, 2012.

J. Schulze and U. Sonnenborn, Yeasts in the gut: from commensals to infectious agents, Dtsch Ärztebl Int, vol.106, pp.837-842, 2009.

B. Segal and . Aspergillosis, Aspergillosis, New England Journal of Medicine, vol.360, issue.18, pp.1870-1884, 2009.
DOI : 10.1056/NEJMra0808853

J. Blanquer and B. Galván, Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient, Rev Esp Quimioter Publ Of Soc Esp Quimioter, vol.26, pp.173-188, 2013.

G. Martin, D. Mannino, S. Eaton, and M. Moss, The Epidemiology of Sepsis in the United States from 1979 through 2000, New England Journal of Medicine, vol.348, issue.16, pp.1546-1554, 1979.
DOI : 10.1056/NEJMoa022139

P. Tamboli, Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study, Mycoses, vol.56, pp.638-645, 2013.

. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation, Blood, vol.116, pp.5111-5118, 2010.

T. Börjesson, U. Stöllman, and J. Schnürer, Volatile metabolites produced by six fungal species compared with other indicators of fungal growth on cereal grains, Appl Environ Microbiol, vol.58, pp.2599-2605, 1992.

M. Canuto, M. , G. Rodero, and F. , Antifungal drug resistance to azoles and polyenes, The Lancet Infectious Diseases, vol.2, issue.9, pp.550-563, 2002.
DOI : 10.1016/S1473-3099(02)00371-7

C. Sheng, Z. Miao, J. H. Yao, J. Wang, W. Che et al., Three-Dimensional Model of Lanosterol 14??-Demethylase from Cryptococcus neoformans: Active-Site Characterization and Insights into Azole Binding, Antimicrobial Agents and Chemotherapy, vol.53, issue.8, pp.3487-3495, 2009.
DOI : 10.1128/AAC.01630-08

A. Warrilow, J. Parker, D. Kelly, and S. Kelly, Azole affinity of sterol 14?- demethylase (CYP51) enzymes from Candida albicans and Homo sapiens

E. Johnson, A. Espinel-ingroff, A. Szekely, H. Hockey, and P. Troke, Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763

Q. Sun, A. Fothergill, D. Mccarthy, M. Rinaldi, and J. Graybill, In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes, Antimicrobial Agents and Chemotherapy, vol.46, issue.5, pp.1581-1582, 2002.
DOI : 10.1128/AAC.46.5.1581-1582.2002

M. Pfaller, S. Messer, L. Boyken, R. Hollis, C. Rice et al., In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program, Diagnostic Microbiology and Infectious Disease, vol.48, issue.3, pp.201-205, 2004.
DOI : 10.1016/j.diagmicrobio.2003.09.008

M. Nguyen and C. Yu, Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole, Journal of Antimicrobial Chemotherapy, vol.42, issue.2, pp.253-256, 1998.
DOI : 10.1093/jac/42.2.253

F. Sabatelli, R. Patel, P. Mann, C. Mendrick, C. Norris et al., In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts, Antimicrobial Agents and Chemotherapy, vol.50, issue.6, pp.2009-2015, 2006.
DOI : 10.1128/AAC.00163-06

S. Natesan, A. Lamichchane, S. Swaminathan, and W. Wu, Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus, Diagnostic Microbiology and Infectious Disease, vol.76, issue.4, pp.458-463, 2013.
DOI : 10.1016/j.diagmicrobio.2013.04.022

R. Rajendran, E. Mowat, E. Mcculloch, D. Lappin, B. Jones et al., Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity, Antimicrobial Agents and Chemotherapy, vol.55, issue.5, pp.2092-2097, 2011.
DOI : 10.1128/AAC.01189-10

A. Lupetti, R. Danesi, M. Campa, D. Tacca, M. Kelly et al., Molecular basis of resistance to azole antifungals, Trends in Molecular Medicine, vol.8, issue.2, pp.76-81, 2002.
DOI : 10.1016/S1471-4914(02)02280-3

D. Sanglard, F. Ischer, M. Monod, and J. Bille, Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene, Microbiology, vol.143, issue.2, pp.405-416, 1997.
DOI : 10.1099/00221287-143-2-405

J. Lopez-ribot, R. Mcatee, L. Lee, W. Kirkpatrick, T. White et al., Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis, Antimicrob Agents Chemother, vol.42, pp.2932-2937, 1998.

S. Perea, J. López-ribot, W. Kirkpatrick, R. Mcatee, R. Santillán et al., Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.45, issue.10, pp.2676-2684, 2001.
DOI : 10.1128/AAC.45.10.2676-2684.2001

E. Manavathu, M. Ramesh, I. Baskaran, L. Ganesan, and P. Chandrasekar, A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans, Journal of Antimicrobial Chemotherapy, vol.53, issue.2, pp.386-389, 2004.
DOI : 10.1093/jac/dkh066

M. Rodríguez, E. Calvo, C. Serena, M. Mariné, F. Pastor et al., Effects of Double and Triple Combinations of Antifungal Drugs in a Murine Model of Disseminated Infection by Scedosporium prolificans, Antimicrobial Agents and Chemotherapy, vol.53, issue.5, pp.2153-2155, 2009.
DOI : 10.1128/AAC.01477-08

D. Maccallum, J. Whyte, and F. Odds, Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis, Antimicrobial Agents and Chemotherapy, vol.49, issue.9, pp.3697-3701, 2005.
DOI : 10.1128/AAC.49.9.3697-3701.2005

K. Clemons, M. Espiritu, R. Parmar, and D. Stevens, Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis, Antimicrobial Agents and Chemotherapy, vol.49, issue.12, pp.4867-4875, 2005.
DOI : 10.1128/AAC.49.12.4867-4875.2005

C. Padoin and O. Tribut, Pharmacocinétique (PK)/pharmacodynamie (PD) et place du suivi thérapeutique pharmacologique (STP) des antifongiques. Médecine thérapeutique, pp.329-339, 2010.

S. Trifilio, G. Pennick, J. Pi, J. Zook, M. Golf et al., Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients, Cancer, vol.44, issue.8, pp.1532-1535, 2007.
DOI : 10.1002/cncr.22568

M. Grudzie?, K. Pa?ka, F. Pluci?ski, and A. Mazurek, Molecular properties impact on bioavailability of second generation triazoles antifungal agents, Acta Pol Pharm, vol.70, pp.869-872, 2013.

. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype, Br J Clin Pharmacol, vol.68, pp.906-915, 2009.

S. Dunzendorfer, Human tissue distribution of voriconazole, Antimicrob Agents Chemother, vol.55, pp.925-928, 2011.

Z. Desta, X. Zhao, J. Shin, and D. Flockhart, Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism, Clinical Pharmacokinetics, vol.32, issue.4, pp.913-958, 2002.
DOI : 10.2165/00003088-200241120-00002

J. Rengelshausen, CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole, J Clin Pharmacol, vol.49, pp.196-204, 2009.

S. Lee, B. Kim, N. W. Yoon, S. Cho, J. Shin et al., Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.13, issue.2-3, pp.195-203, 2011.
DOI : 10.1177/0091270010395510

D. , R. M. Tozer, and T. , In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3 In vivo evaluation of Michaelis-Menten constants of hepatic drug-eliminating systems, Drug Metab Dispos Biol Fate Chem. Drug Metab Dispos Biol Fate Chem, vol.386, pp.25-31197, 1978.

H. Sanchez-ruiz, Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function, J Chemother Florence Italy, vol.20, pp.93-100, 2008.

V. Mach, M. Burhenne, J. Weilemann, and L. , Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy, BMC Clinical Pharmacology, vol.56, issue.Suppl 1, p.6, 2006.
DOI : 10.1046/j.1365-2125.2003.01993.x

. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies, Clin Drug Investig, vol.28, pp.409-420, 2008.

D. Neofytos, L. Lombardi, R. Shields, D. Ostrander, L. Warren et al., Administration of Voriconazole in Patients With Renal Dysfunction, Clinical Infectious Diseases, vol.54, issue.7, pp.913-921, 2012.
DOI : 10.1093/cid/cir969

E. Koselke, S. Kraft, J. Smith, and J. Nagel, Evaluation of the effect of obesity on voriconazole serum concentrations, Journal of Antimicrobial Chemotherapy, vol.67, issue.12, pp.2957-2962, 2012.
DOI : 10.1093/jac/dks312

P. Delaunay and C. Fissore, Systemic antifungal drug interactions, J de Myc Med, pp.152-158, 2006.

. Disponible-À, K. Tan, L. Purkins, G. Layton, J. Hamlin et al., Effect of omeprazole on the steady-state pharmacokinetics of voriconazole, Br J Clin Pharmacol, vol.1356, pp.56-61, 2003.

N. Boyd, C. Zoellner, M. Swancutt, and K. Bhavan, Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections, Antimicrobial Agents and Chemotherapy, vol.56, issue.11, pp.6001-6002, 2012.
DOI : 10.1128/AAC.00700-12

P. Wilson, Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Rev Esp Cardiol Engl Ed, vol.61, issue.82, p.1329, 2008.

K. Mahalati, P. Belitsky, I. Sketris, K. West, and R. Panek, NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVE, Transplantation, vol.68, issue.1
DOI : 10.1097/00007890-199907150-00011

R. Motzer, M. Mazumdar, J. Sheinfeld, D. Bajorin, H. Macapinlac et al., Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients, Journal of Clinical Oncology, vol.18, issue.6, pp.1173-11780, 2000.
DOI : 10.1200/JCO.2000.18.6.1173

S. Miyakis, S. Van-hal, J. Ray, and D. Marriott, Voriconazole concentrations and outcome of invasive fungal infections, Clinical Microbiology and Infection, vol.16, issue.7, pp.927-933, 2010.
DOI : 10.1111/j.1469-0691.2009.02990.x

T. Okuda, A. Okuda, N. Watanabe, M. Takao, and K. Takayanagi, Retrospective Serological Tests for Determining the Optimal Blood Concentration of Voriconazole for Treating Fungal Infection, YAKUGAKU ZASSHI, vol.128, issue.12, pp.1811-1818, 2008.
DOI : 10.1248/yakushi.128.1811

I. Lutsar, M. Hodges, K. Tomaszewski, P. Troke, and N. Wood, Safety of Voriconazole and Dose Individualization, Clinical Infectious Diseases, vol.36, issue.8, pp.1087-1088, 2003.
DOI : 10.1086/374248

L. Dolomie-fagour, J. Corcuff, L. Jensen, and J. Kristensen, Is free plasmatic cortisol measurement useful in intensive care unit? In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis, Ann Biol Clin. J Pharm Sci, vol.66102, pp.31-412882, 2008.

Z. Liu, F. Li, and Y. Huang, Determination of unbound drug concentration and protein-drug binding fraction in plasma, Biomedical Chromatography, vol.13, issue.4, pp.262-266, 1999.
DOI : 10.1002/(SICI)1099-0801(199906)13:4<262::AID-BMC832>3.0.CO;2-2

G. Wolfer, . Jr, and W. Rippon, Protocols for use of ultrafiltration in determination of free ligand concentration and of complexity of ligand/protein interactions, Clin Chem, vol.33, pp.115-117, 1987.

C. Arellano, P. Gandia, T. Lafont, R. Jongejan, and E. Chatelut, Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC???MS/MS assay and ultrafiltration method, Journal of Chromatography B, vol.907, pp.94-100, 2012.
DOI : 10.1016/j.jchromb.2012.09.007

B. Brodie, Displacement of one drug by another from carrier or receptor sites

N. Takamura, T. Maruyama, and M. Otagiri, Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia, Clin Chem, vol.43, pp.2274-2280, 1997.

S. Chan and B. Gerson, Free drug monitoring, Clin Lab Med, vol.7, pp.279-287, 1987.

H. Booker and D. B. , Serum Concentrations of Free Diphenylhydantoin and their Relationship To Clinical Intoxication, Epilepsia, vol.13, issue.2, pp.177-184, 1973.
DOI : 10.1111/j.1528-1157.1973.tb03954.x

B. Gidal, D. Collins, and B. Beinlich, Apparent Valproic Acid Neurotoxicity in a Hypoalbuminemic Patient, Annals of Pharmacotherapy, vol.27, issue.1, pp.32-35, 1993.
DOI : 10.1177/106002809302700107

J. Haroldson, L. Kramer, D. Wolff, and K. Lake, Elevated Free Fractions of Valproic Acid in a Heart Transplant Patient with Hypoalbuminemia, Annals of Pharmacotherapy, vol.274, issue.2, pp.183-187, 2000.
DOI : 10.1345/aph.19147

K. Chan and R. Beran, Value of therapeutic drug level monitoring and unbound (free) levels, Seizure, vol.17, issue.6, pp.572-575, 2008.
DOI : 10.1016/j.seizure.2007.12.007

J. Lindow and E. Wijdicks, Phenytoin Toxicity Associated With Hypoalbuminemia in Critically Ill Patients, Chest, vol.105, issue.2, pp.602-604, 1994.
DOI : 10.1378/chest.105.2.602

S. Zielmann, F. Mielck, R. Kahl, S. Kazmaier, M. Sydow et al., A Rational Basis for the Measurement of Free Phenytoin Concentration in Critically I11 Trauma Patients, Therapeutic Drug Monitoring, vol.16, issue.2, pp.139-144, 1994.
DOI : 10.1097/00007691-199404000-00005

F. Akhlaghi and A. Trull, Distribution of Cyclosporin in Organ Transplant Recipients, Clinical Pharmacokinetics, vol.3, issue.9
DOI : 10.2165/00003088-200241090-00001

H. Zahir, G. Mccaughan, M. Gleeson, R. Nand, and A. Mclachlan, Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation, Therapeutic Drug Monitoring, vol.26, issue.5, pp.506-515, 2004.
DOI : 10.1097/00007691-200410000-00008

H. Zahir, G. Mccaughan, M. Gleeson, R. Nand, and A. Mclachlan, Factors affecting variability in distribution of tacrolimus in liver transplant recipients, British Journal of Clinical Pharmacology, vol.30, issue.3, pp.298-309, 2004.
DOI : 10.1046/j.1365-2125.2003.02008.x

B. Atcheson, P. Taylor, D. Mudge, D. Johnson, C. Hawley et al., Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant, British Journal of Clinical Pharmacology, vol.11, issue.3, pp.271-280, 2005.
DOI : 10.1034/j.1399-0012.2001.150607.x

P. Jacobson, J. Long, J. Rogosheske, C. Brunstein, and D. Weisdorf, High Unbound Mycophenolic Acid Concentrations in a Hematopoietic Cell Transplantation Patient with Sepsis and Renal and Hepatic Dysfunction, Biology of Blood and Marrow Transplantation, vol.11, issue.12, pp.977-978, 2005.
DOI : 10.1016/j.bbmt.2005.08.037

B. Sendid, M. Tabouret, J. Poirot, D. Mathieu, J. Fruit et al., New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis, J Clin Microbiol, vol.37, pp.1510-1517, 1999.

Y. Suzuki, I. Tokimatsu, Y. Sato, K. Kawasaki, Y. Sato et al., Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity, Clinica Chimica Acta, vol.424, pp.119-122, 2013.
DOI : 10.1016/j.cca.2013.05.025

K. Matsumoto, K. Ikawa, K. Abematsu, N. Fukunaga, K. Nishida et al., Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes, International Journal of Antimicrobial Agents, vol.34, issue.1, pp.91-94, 2009.
DOI : 10.1016/j.ijantimicag.2009.01.008

D. Araujo, B. Da-silva, C. Haas, S. , D. Costa et al., Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats, International Journal of Antimicrobial Agents, vol.33, issue.2, pp.154-159, 2009.
DOI : 10.1016/j.ijantimicag.2008.08.020

L. Benet and B. Hoener, Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.115-121, 2002.
DOI : 10.1067/mcp.2002.121829

J. Roberts, F. Pea, and . J. Lipman, The Clinical Relevance of Plasma Protein Binding Changes, Clinical Pharmacokinetics, vol.3, issue.2, pp.1-8, 2013.
DOI : 10.1007/s40262-012-0018-5

A. Bousquet-mélou and P. Toutain, Plamsa protein binding displacement interactions are no longer what they used to be, La let du Pharmaco, pp.44-60, 2012.

A. Imhof, D. Schaer, U. Schanz, and U. Schwarz, 110 Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring, International Journal of Infectious Diseases, vol.10, pp.739-742, 2006.
DOI : 10.1016/S1201-9712(06)80107-4

M. Boisdron-celle, A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients, Clin Cancer ANNEXES Annexe, vol.1